STOCKHOLM3 reflex testing

1. STOCKHOLM3 reflex testing decreases prostate biopsy in humans (from 0.6% to 0.4%).

   “biopsy rates decreased from 0.6% to 0.4% (RP 0.67; 95% CI, 0.41-1.07)”

   Human trialPSA ≥2 ng/mlmales

   Reducing MRI Use in Organized Prostate Cancer Testing Using Blood-based Biomarkers: The OPT Stockholm3 Study

   European urology oncology·7 Aug 2026

More on Prostate biopsy

1. STOCKHOLM3 reflex testing decreases magnetic resonance imaging in humans (-64% (from 2.7% to 1.0%)).

   “MRI use decreased by 64%, from 2.7% (181/6663) in 2023 to 1.0% (70/7070) in 2024 (RP 0.36; 95% confidence intervals [CI], 0.28-0.48)”

   Human trialPSA ≥2 ng/mlmales

   Reducing MRI Use in Organized Prostate Cancer Testing Using Blood-based Biomarkers: The OPT Stockholm3 Study

   European urology oncology·7 Aug 2026

More on Magnetic resonance imaging